This report analyses the financial performance of Isolit-Bravo for the 2019. You will find all the necessary details regarding company's profitability, volume growth, indebtedness and a comparison with selected peers.
Isolit-Bravo announced a net profit of CZK 106 mil in 2019, up 2.22% when compared to the last year. Sales decreased 8.80% yoy to CZK 846 mil, EBITDA rose 19.1% to CZK 221 mil and net margin amounted to 12.6%. In the last three years, the Company grew its revenues by -9.18% a year, and produced an average return on capital of 14.3% and return on equity of 9.64%.
The key highlights are:
Sales decreased 8.80% yoy to CZK 846 mil in 2019. That’s compared to average growth of -9.18% in the last three years and 11.5% less when compared to the average annual increase in the last decade.
EBITDA amounted to CZK 221 mil and grew 19.1% when compared to last year. EBITDA margin reached 26.1%, up 0.393%pp when compared to a 5-year average.
Company’s indebtedness fell when measured by Net Debt/Equity and reached -65.6% at the end of 2019. When compared to EBITDA, net debt fell to -3.27x at the end of 2019.
Isolit-Bravo netted CZK 106 mil to its shareholders in the last year, up 2.20% when compared to the average seen in the last five years. The company produced a return on capital of 15.2% and return on equity of 9.88% in the last year. Since 2014, Isolit-Bravo’s average ROCE amounted to 12.7% and ROE 8.96%.
When compared to selected peers, Isolit-Bravo has grown 9.01 pp slower in sales in the last five years. It was also 2.12 pp more profitable in terms of ROCE, and achieved 5.87 pp higher EBITDA margin based on a last year's results.
In terms of indebtedness, the company operated with 67.1 pp lower net debt to equity at the end of 2019 when compared to its peers (-65.6% at Isolit-Bravo vs. 1.50% of its peers).
Helgi Library 
